Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 8/2012

01-08-2012 | Letter to the Editors

Value of MRI as a surrogate marker for PML in natalizumab long-term therapy

Authors: I. Ayzenberg, C. Lukas, N. Trampe, R. Gold, K. Hellwig

Published in: Journal of Neurology | Issue 8/2012

Login to get access

Excerpt

Dear Sir, …
Literature
1.
Vermersch P, Kappos L, Gold R, Foley JF, Olsson T, Cadavid D et al (2011) Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76(20):1697–1704PubMedCrossRef
2.
Clifford DB, De Luca A, DeLuca A, Simpson DM, Arendt G, Giovannoni G et al (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9(4):438–446PubMedCrossRef
3.
Lindå H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T et al (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361(11):1081–1087PubMedCrossRef
4.
Vaklavas C, Sotelo-Rafiq EP, Lovy J, Escobar MA, Tsimberidou AM (2010) Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. Virol J 7:256PubMedCrossRef
5.
Kleiter I, Schröder M, Lürding R, Schuierer G, Clifford DB, Bogdahn U et al (2010) Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy. Mult Scler 16(6):749–753PubMedCrossRef
Metadata
Title
Value of MRI as a surrogate marker for PML in natalizumab long-term therapy
Authors
I. Ayzenberg
C. Lukas
N. Trampe
R. Gold
K. Hellwig
Publication date
01-08-2012
Publisher
Springer-Verlag
Published in
Journal of Neurology / Issue 8/2012
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-012-6426-5

Other articles of this Issue 8/2012

Journal of Neurology 8/2012 Go to the issue

Review

Interleukin-1A −889C/T polymorphism and risk of Alzheimer’s disease: a meta-analysis based on 32 case–control studies

Letter to the Editors

Diagnostic pitfalls: a case of neurosarcoidosis mimicking tuberculous meningitis

Original Communication

Delirium in acute stroke: screening tools, incidence rates and predictors: a systematic review

Original Communication

Fractional anisotropy in the centrum semiovale as a quantitative indicator of cerebral white matter damage in the subacute phase in patients with carbon monoxide poisoning: correlation with the concentration of myelin basic protein in cerebrospinal fluid

Original Article

Validation of the Comprehensive International Classification of Functioning, Disability, and Health Core Set for multiple sclerosis from the perspective of physicians

Letter to the Editors

Focal CT hypoperfusion in HaNDL